Denali Therapeutics (DNLI) Amortizatization of Intangibles (2017 - 2026)
Denali Therapeutics (DNLI) reported Amortizatization of Intangibles of $916000.0 for Q1 2026, up 3.27% year-over-year from $887000.0 in Q1 2025, and down 1.4% quarter-over-quarter from $929000.0 in Q4 2025.
Denali Therapeutics (DNLI) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Amortizatization of Intangibles data on file, last reported at $916000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $916000.0, up 3.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (up 74.9% YoY), and the FY2025 annual result was $3.6 million, up 203.17% from the prior year.
- Amortizatization of Intangibles slipped to $916000.0 in Q1 2026 per DNLI's latest filing, from $929000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $11.5 million in Q2 2023 and troughed at -$1.6 million in Q1 2022.
- A 5-year average of $1.9 million and a median of $900000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles tumbled 40.14% in 2022, then jumped 2448.88% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $1.4 million in 2022, then soared by 706.5% to $11.5 million in 2023, then tumbled by 93.09% to $797000.0 in 2024, then climbed by 16.56% to $929000.0 in 2025, then retreated by 1.4% to $916000.0 in 2026.
- Business Quant data shows DNLI's Amortizatization of Intangibles at $916000.0 in Q1 2026, $929000.0 in Q4 2025, and $900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | 916,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 916,000.00 |
| Mar 31, 2026 | 916,000.00 |
| Dec 31, 2025 | 929,000.00 |
| Dec 31, 2025 | 929,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 887,000.00 |
| Mar 31, 2025 | 887,000.00 |
| Dec 31, 2024 | 797,000.00 |
| Dec 31, 2024 | 797,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2023 | 11.53 Mn |
| Jun 30, 2023 | 11.53 Mn |
| Mar 31, 2023 | 7.85 Mn |
| Mar 31, 2023 | 7.85 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Dec 31, 2022 | 1.43 Mn |